Ventana Medical Systems, Inc.
Most Admired Company: 2013, 2016
Top Arizona executive: Ann Costello, president
What it does: Innovator of tissue-based diagnostic solutions.
Admirable quality: Ventana is helping unlocking the DNA of cancer. In 2016, the VENTANA PD-L1 test received U.S. Food and Drug Administration approval for use as a complementary diagnostic to provide PD-L1 status on patients with metastatic urothelial cancer. It’s the first major advancement in more than 30 years in the treatment of urothelial cancer and is anticipated to be the foundational complementary test for Roche’s TECENTRIQ therapy in other cancer indications.
